Gilead sets pricing for coronavirus drug remdesivir, could cost over $3G
Just days after getting conditional approval for its coronavirus drug remdesivir in Europe, Gilead has announced pricing for the U.S. and other developed countries, charging different rates for the U.S. federal government and private insurers.
Read More: https://ift.tt/31sxXR6